You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH):JS116膠囊臨牀試驗申請獲受理

格隆匯3月28日丨君實生物(688180.SH)公佈,近日,公司收到國家藥監局核准簽發的《受理通知書》,JS116膠囊的臨牀試驗申請獲得受理。

JS116為具有全新結構的KRAS G12C小分子不可逆共價抑制劑,用於治療KRAS G12C突變的非小細胞性肺癌(NSCLC)患者。KRAS基因突變有不同的亞型,其中KRAS G12C佔所有KRAS突變的44%,在非小細胞肺癌中最為常見。臨牀前研究表明,JS116具有較寬的安全窗,良好的有效性和安全性,有望成為安全、高效的精準靶向治療藥物。

2020年11月,公司與成都華健未來科技有限公司簽署《技術許可及合作協議》,公司通過獨佔許可方式獲得JS116在合作區域(全部亞洲國家和地區)內的權益,包括但不限於在合作區域內的研發、生產(包括委託生產)、臨牀研究以及商業化的權利。截至本公吿披露日,全球僅有一款針對KRAS G12C的靶向藥Lumakras®(Sotorasib,安進公司產品)獲批上市,用於治療至少經過一次系統治療的KRAS G12C突變的晚期非小細胞肺癌,國內尚無KRAS G12C小分子抑制劑獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account